<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="137780">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01797081</url>
  </required_header>
  <id_info>
    <org_study_id>191622-114</org_study_id>
    <nct_id>NCT01797081</nct_id>
  </id_info>
  <brief_title>BOTOX速 in the Treatment of Crow's Feet Lines in Japan</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <authority>Japan: Pharmaceuticals and Medical Devices Agency</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety and efficacy of BOTOX速 (botulinum toxin Type A) compared
      to placebo for the treatment of Crow's Feet Lines (Lateral Canthal Rhytides).
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">July 2014</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Investigator's Assessment of the Severity of Crow's Feet Lines at Maximum Smile Using the Facial Wrinkle Scale</measure>
    <time_frame>Day 30</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Investigator's Assessment of the Severity of Crow's Feet Lines at Rest Using the Facial Wrinkle Scale</measure>
    <time_frame>Day 30</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject's Assessment of Appearance of Crow's Feet Lines as Measured by the Facial Line Outcomes Questionnaire</measure>
    <time_frame>Day 30</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject's Assessment of Age-related Facial Appearance as Measured by the Self-Perception of Age Questionnaire</measure>
    <time_frame>Day 30</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">300</enrollment>
  <condition>Lateral Canthus Rhytides</condition>
  <condition>Crow's Feet Lines</condition>
  <arm_group>
    <arm_group_label>Botulinum toxin Type A (24 U)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>24 units botulinum toxin Type A (total dose) injected into bilateral Crow's Feet Line areas on Day 1. Based on retreatment criteria participants were eligible for up to 5 treatment cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Botulinum toxin Type A (12 U)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12 units botulinum toxin Type A (total dose) injected into bilateral Crow's Feet Line areas on Day 1. Based on retreatment criteria participants were eligible for up to 5 treatment cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo/Botulinum toxin Type A (24 U)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Placebo (normal saline) one treatment injected into bilateral Crow's Feet Line areas on Day 1 and subsequent treatments if applicable until day 180. Botulinum toxin Type A (24 U) injected into bilateral Crow's Feet Line areas at any additional treatments from day 180 onward. Based on retreatment criteria participants were eligible for up to 5 treatment cycles (2 Placebo + 3 botulinum toxin type A).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo/Botulinum toxin Type A (12 U)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Placebo (normal saline) one treatment injected into bilateral Crow's Feet Line areas on Day 1 and subsequent treatments if applicable until day 180. Botulinum toxin Type A (12 U) injected into bilateral Crow's Feet Line areas at any additional treatments from day 180 onward. Based on retreatment criteria participants were eligible for up to 5 treatment cycles (2 Placebo + 3 botulinum toxin type A).</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>botulinum toxin Type A (24 U)</intervention_name>
    <description>24 units botulinum toxin Type A (total dose) injected into bilateral Crow's Feet Line areas per treatment.</description>
    <arm_group_label>Botulinum toxin Type A (24 U)</arm_group_label>
    <arm_group_label>Placebo/Botulinum toxin Type A (24 U)</arm_group_label>
    <other_name>BOTOX速</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>botulinum toxin Type A (12 U)</intervention_name>
    <description>12 units botulinum toxin Type A (total dose) injected into bilateral Crow's Feet Line areas per treatment.</description>
    <arm_group_label>Botulinum toxin Type A (12 U)</arm_group_label>
    <arm_group_label>Placebo/Botulinum toxin Type A (12 U)</arm_group_label>
    <other_name>BOTOX速</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Normal Saline</intervention_name>
    <description>Normal saline (placebo) injected into bilateral Crow's Feet Line areas per treatment.</description>
    <arm_group_label>Placebo/Botulinum toxin Type A (24 U)</arm_group_label>
    <arm_group_label>Placebo/Botulinum toxin Type A (12 U)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        -Moderate to severe Crow's Feet Lines

        Exclusion Criteria:

          -  Current or previous botulinum toxin treatment of any serotype

          -  Diagnosis of myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis

          -  Facial laser or light treatment for cosmetic purposes, microdermabrasion, superficial
             peels, or topical retinoid therapy or hormone cream within 3 months

          -  Laser treatment or phototherapy of the face for medical purposes, blepharoplasty,
             brow-lift or related procedure, periorbital permanent make-up, or oral retinoid
             therapy within one year

          -  Medium-depth or deep facial peels within 5 years

          -  Prior facial cosmetic surgery (e.g., prior periorbital surgery, facial lift,
             periorbital treatment with fillers, implantation or transplantation)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>August 6, 2013</lastchanged_date>
  <firstreceived_date>February 20, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>Botulinum Toxins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
